Disease:  Large B-cell lymphoma

Indication:  Patients up to 25 years of age with B-cell precursor acute lymphoblasticleukemia (ALL) that is refractory or in second or later relapse.

Company:  Novartis Pharmaceuticals

  • Market Cap: $198.098B Oct 2020

Methods:  Patient’s T cells are modified to recognize CD19 on B cells, expanded, and reintroduced to the patient to combat Large B-cell Lymphoma.

Link to the clinical trial:  NCT04161118

Current Phase:  FDA Approved

Subscribe to Our Newsletter

Subscribe to our newsletter to keep up to date with all the latest news about AGT!

[formidable id=9]

Follow AGT on Social Media